Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DNA X, Inc.SONM · Entity 8261 | Director | April 23, 2025 | April 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DNA X, Inc.
Report date April 23, 2025 · Filed April 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 49,139 |
Reported balance
After 2025-04-23 transaction · row 1
1 source rowRow 1 · 2025-04-23 · Sale · Disposed 23,381 · Balance 49,139 F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are mandated by the Issuer's election under its equity incentive plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.42 to $1.45, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are mandated by the Issuer's election under its equity incentive plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.42 to $1.45, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 23, 2025 Filed Apr 25, 2025 12:35 UTC | DNA X, Inc. SONM · Entity 8261 | SaleCommon Stock | 23,381 | $1.45 | $33,902.45 |
DisclosureSEC source: 0001641172-25-006119 · ownership.xml · nonDerivative · entry 1 Steenstra Jack · CIK 0001936052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,139 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are mandated by the Issuer's election under its equity incentive plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.42 to $1.45, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 20:30 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 46,728 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-002389 · ownership.xml · nonDerivative · entry 1 Steenstra Jack · CIK 0001936052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,520 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the 45th day following the date of the grant, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Consists of (i) 14,770 shares of common stock and (ii) 57,750 unvested restricted stock units. Read SEC document |
| July 19, 2024 Filed Jul 23, 2024 12:05 UTC | DNA X, Inc. SONM · Entity 8261 | SaleCommon Stock | 1,623 | $3.67 | $5,956.41 |
DisclosureSEC source: 0001493152-24-028778 · ownership.xml · nonDerivative · entry 1 Steenstra Jack · CIK 0001936052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,792 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are mandated by the Issuer's election under its equity incentive plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.67 to $3.72, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Consists of (i) 14,770 shares of common stock and (ii) 11,022 unvested restricted stock units. F4 · balance_after: The number of securities reported herein reflects the effects of a 1-for-10 reverse stock split effected by the Issuer on July 17, 2024, which was exempt from reporting pursuant to Rule 16a-9. Read SEC document |
| June 21, 2024 Filed Jun 24, 2024 20:25 UTC | DNA X, Inc. SONM · Entity 8261 | SaleCommon Stock | 35,882 | $0.69 | $24,758.58 |
DisclosureSEC source: 0001493152-24-024962 · ownership.xml · nonDerivative · entry 2 Steenstra Jack · CIK 0001936052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,145 F3 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales are mandated by the Issuer's election under its equity incentive plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.69 to $0.74, inclusive. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a securityholder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · balance_after: Consists of (i) 132,649 shares of common stock and (ii) 141,496 unvested restricted stock units. Read SEC document |
| June 20, 2024 Filed Jun 24, 2024 20:25 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 78,947 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-024962 · ownership.xml · nonDerivative · entry 1 Steenstra Jack · CIK 0001936052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,027 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of the Issuer, or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Consists of (i) 168,531 shares of common stock and (ii) 141,496 unvested restricted stock units. Read SEC document |
| September 28, 2023 Filed Sep 29, 2023 23:01 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 89,525 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-034935 · ownership.xml · nonDerivative · entry 1 Steenstra Jack · CIK 0001936052 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 231,080 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of the Issuer, or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Consists of (i) 79,006 shares of common stock and (ii) 152,074 unvested restricted stock units. Read SEC document |
| November 18, 2022 Filed Nov 22, 2022 02:45 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 47,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-033218 · ownership.xml · nonDerivative · entry 1 Steenstra Jack · CIK 0001936052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,555 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of Sonim Technologies, Inc. (the "Issuer") or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 05, 2022 Filed Aug 9, 2022 23:13 UTC | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 85,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-021816 · ownership.xml · nonDerivative · entry 1 Steenstra Jack · CIK 0001936052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,714 F1 · shares: Represents the grant of restricted stock units that vest in one installment on the earlier of the first anniversary of the grant date, immediately prior to the next annual meeting of stockholders, a change in control of Sonim Technologies, Inc. (the "Issuer") or the Reporting Person's death or disability, subject to the Reporting Person's continued service to the Issuer. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 05, 2022 Filed Oct 14, 2022 20:06 UTC Amendment | DNA X, Inc. SONM · Entity 8261 | GrantCommon Stock | 93,823 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-028455 · ownership.xml · nonDerivative · entry 1 Steenstra Jack · CIK 0001936052 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,823 F1 · shares: The Reporting Person's previously filed Form 4 inadvertently (i) understated the number of shares of common stock of Sonim Technologies, Inc. (the "Issuer") disclosed in Columns 4 and 5 by 8,109 shares due to a mathematical error in the calculation of the value of shares for the purpose of issuance and (ii) incorrectly described the vesting schedule of issued restricted stock units (the "RSUs"). The RSUs vest in three equal annual installments on the anniversary date on which the Reporting Person was appointed as a director of the Issuer's board, subject to continuous service on each vesting date. This Form 4 corrects the above-described errors by increasing the number of shares and the total amount of securities beneficially owned by the Reporting Person. F1 · balance_after: The Reporting Person's previously filed Form 4 inadvertently (i) understated the number of shares of common stock of Sonim Technologies, Inc. (the "Issuer") disclosed in Columns 4 and 5 by 8,109 shares due to a mathematical error in the calculation of the value of shares for the purpose of issuance and (ii) incorrectly described the vesting schedule of issued restricted stock units (the "RSUs"). The RSUs vest in three equal annual installments on the anniversary date on which the Reporting Person was appointed as a director of the Issuer's board, subject to continuous service on each vesting date. This Form 4 corrects the above-described errors by increasing the number of shares and the total amount of securities beneficially owned by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.